论文部分内容阅读
在过去15～20年中,恶性淋巴瘤的病理生理学,包括免疫学、细胞遗传学、病毒病因学等,均有显著进展,在临床治疗方面,则进展相对缓慢。本文将对非何杰金淋巴瘤(NHL)的治疗进行评价,并探讨今后的趋势。按照国际工作分类(1982)的三级,分别讨论如下。一、低度恶性组根据欧美文献,本组病例约占NHL的1/3左右,其中滤泡性小裂细胞为主型占70%,滤泡性小裂与大细胞混合型25%,小细胞型5%。根据我国学者最近对2035例B细胞NHL的分析,滤泡性全部病例与
In the past 15 to 20 years, the pathophysiology of malignant lymphoma, including immunology, cytogenetics, viral etiology and so on, have made significant progress in the clinical treatment, the progress is relatively slow. This article will evaluate the treatment of non-Hodgkin’s lymphoma (NHL) and explore future trends. According to the three levels of the International Classification of Work (1982), they are discussed separately. First, the low-grade malignant group According to European and American literature, this group of patients account for about 1/3 of the NHL, which accounted for 70% of the main type of small follicular cells, follicular small cell and mixed 25% of small cells Cell type 5%. According to our scholars recently 2035 cases of B cell NHL analysis, all cases of follicular and